Ibogaine reduces PTSD symptoms through a mechanism distinct from every current first-line treatment. The 2023 Stanford study found 88% average reductions in PTSD symptoms in 30 special operations veterans at one month post-treatment. That number has circulated widely. The clinical context behind it — who those veterans were, what they had already tried, and what the study did not control for — has not.
Ibogaine for PTSD works primarily through fear memory reconsolidation — a process by which traumatic memories are retrieved and re-stored with reduced emotional charge — and by producing broad neuroplasticity through GDNF upregulation. The active experience lasts 12–24 hours. Noribogaine, the active metabolite, sustains those neuroplasticity changes for weeks. Medical screening including EKG is required before any ceremony.
What Ibogaine Does to PTSD at the Neurological Level
PTSD is a disorder of memory storage, not a character failing. The traumatic event is over. The brain's response to it is not.
The amygdala — the brain's threat-detection centre — remains in persistent activation. Everyday triggers are processed as evidence of ongoing danger. The hippocampus, which contextualises memory in time and space, fails to adequately signal that the threat has passed. The result is intrusion, hypervigilance, and avoidance — the three core symptom clusters of PTSD.
Ibogaine works through several overlapping mechanisms.
The first is fear memory reconsolidation. When a memory is retrieved, it briefly becomes unstable and can be re-stored. Ibogaine creates a state of neuroplasticity during which traumatic memories are retrieved without the same intensity of physiological alarm. The factual content of the memory remains intact. Its emotional charge does not.
The second is disruption of the default mode network— the brain's self-referential processing loop, associated with rumination, anticipation of threat, and the narrative structure that maintains traumatic patterns. Ibogaine interrupts this network in a way that no available psychiatric medication approaches.
The third is GDNF upregulation. GDNF (Glial Cell Line-Derived Neurotrophic Factor) is a protein essential to neuroplasticity — the brain's capacity to form new connections and restructure existing patterns. Ibogaine increases GDNF expression. Noribogaine, the active metabolite that remains in the body for weeks after ceremony, sustains that elevation.
A 2025 paper published in Nature Mental Health analysed brain scans from the Stanford cohort and found that veterans who improved in executive function after ibogaine showed increased theta rhythms — associated with neuroplasticity and cognitive flexibility. Reduced cortical complexity correlated with lower hyperarousal. These findings support what practitioners had observed for decades: ibogaine does something to the brain's threat-processing architecture that other treatments do not.
What the Research Shows
The core study is the 2023 Stanford study published in Nature Medicine. The population: 30 special operations veterans with traumatic brain injury, PTSD, and treatment-resistant depression. These were not people who had not tried other things. They had been through VA programmes, been given diagnoses, been prescribed medications.
At one month post-treatment:
- PTSD symptoms: 88% average reduction
- Depression symptoms: 87% average reduction
- Anxiety symptoms: 81% average reduction
- Functional impairment: significant improvement
- Suicidal ideation: significant reduction
Special operations veterans are not, as a population, people who approach things naively. The ones who come to Vancouver — at ceremonies at ExploreBwiti — have been through VA programmes, medication trials, and more diagnoses than they care to count. Many are sceptical that anything is going to work. The Stanford study documented what practitioners had been observing for years: that ibogaine produces changes in this population that conventional treatment does not.
The numbers are striking. So are the limitations. Thirty veterans is not a clinical trial population. There was no placebo arm. The people who travelled to a clinic in Mexico for treatment were self-selected — likely more motivated than the average PTSD population. Citing the Stanford numbers without these caveats is not honest. The data is compelling enough to stand on its own with the caveats included.
Texas committed $50 million in state funding to clinical ibogaine trials at UTMB, UTHealth Houston, Texas A&M University, and Baylor University. Enrollment of up to 300 participants — primarily veterans and first responders — was expected to begin in 2026. That trial will provide the placebo-controlled data the field currently lacks.
The Neuroplasticity Window — and Why Integration Determines the Outcome
The 12–24 hour ceremony is not the treatment. It is the beginning of a window.
Noribogaine — ibogaine's primary active metabolite — remains in the body for weeks to months after ceremony. During this period, the brain is in a state of heightened neuroplasticity. New patterns are more accessible. Old ones are less fixed.
The pattern practitioners observe most often: a person leaves ceremony with reduced hypervigilance, greater emotional range, and what feels like the beginning of something different. Six weeks later, they are back where they started — or worse, because the contrast between what was possible and what they returned to is now sharper.
This happens when people return immediately to the environments, relationships, and unaddressed conditions that produced the PTSD. The ceremony does not resolve ongoing exposure to trauma. It does not change anything outside the window it opens. Integration is the work done to make use of that window before it closes.
Integration coaching at ExploreBwiti is $150–$300 CAD per session, in packages of three or more sessions. It is not an optional extra for people seeking lasting change from PTSD. It is the mechanism through which ceremony translates into durable outcome.
What Medical Screening Requires for PTSD Candidates
PTSD is a psychiatric condition. Ibogaine is a cardiac-active compound. The intersection of those two facts requires thorough preparation before any ceremony.
Medical screening is required for every candidate at ExploreBwiti in Vancouver. This is not a formality. It is how we determine whether ceremony is safe for a specific person.
Required for all candidates:
- EKG and cardiovascular assessment. Ibogaine prolongs the QT interval. An EKG identifies pre-existing QT prolongation, arrhythmia, or other cardiac contraindications before ceremony begins. This step cannot be skipped. The fatalities associated with ibogaine treatment are concentrated among providers who did not conduct cardiac screening.
- Full medical history review
- Blood panel — liver function, kidney function, complete blood count
- Review of all current medications
- Psychiatric history assessment
For PTSD candidates specifically, the psychiatric history assessment carries particular weight. The active experience amplifies what is present. Someone in acute psychiatric instability — active suicidal ideation, severe dissociation, acute psychosis — is not an appropriate candidate for ceremony at this time. The medicine does not produce stability. It tends to intensify what is already there.
Medication review is non-negotiable. SSRIs and SNRIs are absolute contraindications — not preferences to be weighed against desperation. The risk of serotonin syndrome is real and potentially fatal. A supervised taper under physician guidance is required before ceremony. Not a pause. A supervised taper, documented, before the screening conversation concludes.
Who This Is Not For
Some people are not appropriate candidates for ibogaine, regardless of how much they want it.
Absolute contraindications:
- QT prolongation, significant cardiac arrhythmia, or recent myocardial infarction. Identified by EKG. Non-negotiable.
- Current SSRIs or SNRIs without a supervised taper. Serotonin syndrome risk is real and potentially fatal. A supervised taper with the prescribing physician is required — not a pause, a taper.
- Active psychosis or schizophrenia spectrum disorder. The medicine amplifies what is present.
- Severe liver or kidney disease. Impaired organ function slows ibogaine and noribogaine clearance, extending the active experience unpredictably and increasing cardiac risk.
- Lithium and certain other psychiatric medications.
- Pregnancy.
PTSD-specific considerations that disqualify some candidates:
- Acute psychiatric instability. Ceremony is not an appropriate intervention for someone in active crisis. It intensifies what is present. Active suicidal ideation without a stabilisation plan is a disqualifier at this time.
- PTSD that is primarily circumstantial. Ongoing abuse, an unsafe living situation, active trauma exposure — ceremony does not resolve conditions that continue. It is not a buffer against ongoing harm.
Not everyone who applies is an appropriate candidate. Some have cardiac conditions that make ibogaine genuinely dangerous. Some are on medications that cannot be safely tapered in a reasonable timeframe. If you are not an appropriate candidate, we will say so — directly and without softening it. We would rather lose a potential participant than put someone at risk.
The FAQ covers the full contraindications list and what the screening process involves.
Is This Right for You?
The people who benefit most from ibogaine for PTSD share a consistent profile. They have typically tried conventional treatment — therapy, medication, VA programmes — and found it insufficient. They are not in acute crisis. They have the support structure to use the integration window productively. They can commit to the full preparation process and the 2–3 day recovery period that follows.
If that describes your situation, the next step is an application. Every application at ExploreBwiti receives a personal response within 2–3 business days.
The iboga ceremony page explains what the 12–24 hour active experience and recovery period involve in Vancouver. The FAQ covers screening requirements and contraindications in detail. Integration coaching is not an add-on — it is the mechanism through which ceremony produces lasting change. The Stanford study breakdown covers the methodology and what the numbers mean in full. When you are ready to begin the conversation, the application is where it starts.